These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

72 related items for PubMed ID: 16004888

  • 1. Antiproliferative profile of sirolimus and mycophenolate mofetil: impact of the SI/MPL ratio.
    Voisard R, Geçgüner L, Baur R, Herter T, Hombach V.
    Int J Cardiol; 2005 Jul 20; 102(3):435-42. PubMed ID: 16004888
    [Abstract] [Full Text] [Related]

  • 2. Valproic acid inhibits proliferation of human coronary vascular cells (SI/MPL-ratio: 0.5): a novel candidate for systemic and local therapy of postinterventional restenosis.
    Voisard R, Krebs R, Baur R, Hombach V.
    Coron Artery Dis; 2010 Aug 20; 21(5):286-91. PubMed ID: 20508518
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of mycophenolate mofetil on key pattern of coronary restenosis: a cascade of in vitro and ex vivo models.
    Voisard R, Viola S, Kaspar V, Weber CM, von Müller L, Baur R, Gastrock-Balitsch I, Hombach V.
    BMC Cardiovasc Disord; 2005 May 12; 5(1):9. PubMed ID: 15890069
    [Abstract] [Full Text] [Related]

  • 5. [Proliferation effects of sirolimus, cyclosporine A and mycophenolate mofetil on human transitional cell carcinoma cells].
    Lin J, Wang YH, Zhang YH, Tian Y.
    Zhonghua Yi Xue Za Zhi; 2012 Feb 14; 92(6):388-91. PubMed ID: 22490898
    [Abstract] [Full Text] [Related]

  • 6. Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses.
    Berry V, Magill A, Yost M, Janosky J, Sindhi R.
    Cytometry A; 2006 Feb 14; 69(2):95-103. PubMed ID: 16369935
    [Abstract] [Full Text] [Related]

  • 7. Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio.
    Voisard R, Alan M, von Müller L, Baur R, Hombach V.
    BMC Cardiovasc Disord; 2006 Apr 04; 6():14. PubMed ID: 16595000
    [Abstract] [Full Text] [Related]

  • 8. Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro.
    Stracke S, Ramudo L, Keller F, Henne-Bruns D, Mayer JM.
    Transplant Proc; 2006 Apr 04; 38(3):766-70. PubMed ID: 16647466
    [Abstract] [Full Text] [Related]

  • 9. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery.
    Wessely R, Blaich B, Belaiba RS, Merl S, Görlach A, Kastrati A, Schömig A.
    Thromb Haemost; 2007 Jun 04; 97(6):1003-12. PubMed ID: 17549304
    [Abstract] [Full Text] [Related]

  • 10. Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-beta1.
    Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF.
    Transplantation; 2004 Mar 15; 77(5):683-6. PubMed ID: 15021829
    [Abstract] [Full Text] [Related]

  • 11. Direct inhibitory effects of Ganciclovir on ICAM-1 expression and proliferation in human coronary vascular cells (SI/MPL-ratio: >1).
    Voisard R, Münder U, von Müller L, Baur R, Hombach V.
    Med Sci Monit; 2011 Jan 15; 17(1):PI1-6. PubMed ID: 21169918
    [Abstract] [Full Text] [Related]

  • 12. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols.
    Diekmann F, Gutiérrez-Dalmau A, López S, Cofán F, Esforzado N, Ricart MJ, Rossich E, Saval N, Torregrosa JV, Oppenheimer F, Campistol JM.
    Nephrol Dial Transplant; 2007 Aug 15; 22(8):2316-21. PubMed ID: 17452413
    [Abstract] [Full Text] [Related]

  • 13. Conversion to combined therapy with sirolimus and mycophenolate mofetil improved renal function in stable renal transplant recipients.
    Tsai MK, Lee CY, Hu RH, Lee PH.
    J Formos Med Assoc; 2007 May 15; 106(5):372-9. PubMed ID: 17561472
    [Abstract] [Full Text] [Related]

  • 14. Sirolimus and mycophenolate mofetil after liver transplantation.
    Kniepeiss D, Iberer F, Grasser B, Schaffellner S, Tscheliessnigg KH.
    Transpl Int; 2003 Jul 15; 16(7):504-9. PubMed ID: 12687325
    [Abstract] [Full Text] [Related]

  • 15. Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis--implications for post-transplantation bone disease.
    Westenfeld R, Schlieper G, Wöltje M, Gawlik A, Brandenburg V, Rutkowski P, Floege J, Jahnen-Dechent W, Ketteler M.
    Nephrol Dial Transplant; 2011 Dec 15; 26(12):4115-23. PubMed ID: 21622987
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
    El Haggan W, Ficheux M, Debruyne D, Rognant N, Lobbedez T, Allard C, Coquerel A, Ryckelynck JP, Hurault de Ligny B.
    Transplant Proc; 2005 Mar 15; 37(2):864-6. PubMed ID: 15848558
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells.
    Clever YP, Cremers B, Krauss B, Böhm M, Speck U, Laufs U, Scheller B.
    EuroIntervention; 2011 May 15; 7 Suppl K():K32-42. PubMed ID: 22027725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.